Pyxis Oncology Relocates Offices, Hints at Officer Changes
Ticker: PYXS · Form: 8-K · Filed: Jul 3, 2025 · CIK: 1782223
| Field | Detail |
|---|---|
| Company | Pyxis Oncology, Inc. (PYXS) |
| Form Type | 8-K |
| Filed Date | Jul 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-changes, office-relocation
Related Tickers: PYXS
TL;DR
Pyxis Oncology moved its HQ to Boston, MA. Big changes might be coming with officers/directors.
AI Summary
Pyxis Oncology, Inc. announced on July 1, 2025, a change in its principal executive offices to 321 Harrison Avenue, Boston, MA 02118. This filing also indicates potential changes related to directors, officers, and compensatory arrangements, though specific details are not provided in this excerpt.
Why It Matters
A change in principal executive offices can signal operational shifts or growth for a company. The mention of officer and director changes suggests potential strategic realignments.
Risk Assessment
Risk Level: medium — The filing indicates potential changes in leadership and executive compensation, which can introduce uncertainty and risk.
Key Players & Entities
- Pyxis Oncology, Inc. (company) — Registrant
- 321 Harrison Avenue, Boston, MA 02118 (location) — New Principal Executive Offices
- July 01, 2025 (date) — Date of Report
FAQ
What is the new address for Pyxis Oncology's principal executive offices?
The new address is 321 Harrison Avenue, Boston, Massachusetts 02118.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is July 01, 2025.
What is the Commission File Number for Pyxis Oncology, Inc.?
The Commission File Number is 001-40881.
What is the IRS Employer Identification Number (EIN) for Pyxis Oncology, Inc.?
The EIN is 83-1160910.
What specific items are indicated for reporting in this 8-K filing?
The filing indicates reporting for Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; and Compensatory Arrangements of Certain Officers.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 3, 2025 regarding Pyxis Oncology, Inc. (PYXS).